Researchers at Michigan State University have made a significant breakthrough in understanding how ovarian cancer cells evade platinum-based chemotherapy. The team identified a specific protein mechanism that drives treatment resistance and demonstrated that blocking this protein restores drug effectiveness in laboratory models.
Platinum-based chemotherapy remains the standard first-line treatment for ovarian cancer, but a substantial subset of patients develop resistance, limiting therapeutic options. This discovery represents a potentially reversible resistance pathway, opening new avenues for combination therapy strategies. By targeting this protein alongside conventional chemotherapy, clinicians may be able to overcome resistance and improve outcomes for patients with platinum-resistant tumours.
The findings provide a concrete molecular target for future therapeutic development and suggest that resistance mechanisms in ovarian cancer may be more tractable than previously believed.
Was this article helpful?
